Artiva Biotherapeutics, Inc. ARTV

ARTV Company Overview

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, natural killer (NK) cell-based therapies for cancer and autoimmune diseases. The company operates within the biotechnology and cell therapy industries, with a primary emphasis on immunotherapy platforms designed to improve the scalability, accessibility, and consistency of cell-based treatments compared with autologous approaches. Artiva’s core revenue and value drivers are tied to the advancement of its clinical pipeline, intellectual property portfolio, strategic collaborations, and potential future commercialization of NK-cell therapeutics.

The company’s lead programs have focused on combining NK-cell therapies with monoclonal antibodies and other immune-targeting agents to enhance anti-tumor activity. Artiva has positioned itself within the broader cell therapy market by emphasizing off-the-shelf manufacturing capabilities and cryopreserved NK-cell products intended to reduce treatment complexity and manufacturing timelines. The company evolved from earlier research and development efforts in NK-cell biology and entered the public markets through a U.S. initial public offering in 2024. Public disclosures, including SEC filings and investor materials, indicate that the company has concentrated its strategy on scalable allogeneic cell therapy development and clinical-stage execution.